Hereditary angioedema (HAE) is a disease characterized by repeated incidents of swelling (angioedema). The physical signs of the disease include, non-inflammatory swelling of the skin and mucous membrane, that occurs to the subcutaneous tissue in face, arms, buttocks and genitals, and abdominal organs such as stomach, bladder, and urethra. In most of the cases, patients reported that the episodes of swelling worsen over a period of 12 to 24 hours, and usually resolve within 72 hours. The symptoms can persist for up to five days, with the migration of swelling to different sites. It has been observed that the disease is generally unresponsive to antihistamines.
HAE THERAPEUTICS UNDER DEVELOPMENT (2017)
There are many pharmaceutical companies that are using different technologies for better development of drug candidates. These technologies can be helpful in the development of drugs as a single agent therapy. They also allow the development of specific targeted therapies with better drug delivery. For instance, Ionis Pharmaceuticals, Inc. has developed an antisense technology which is efficient and enables the company to create a robust pipeline of antisense drugs to treat patients. Some of the features for the development of the drugs with the help of this technology include, selectively targeted therapy, and less accumulation of drugs in kidneys, liver, and other digestive organs. The rationale for the development of technology is to make available the cost-effective therapies for the treatment to the patients suffering of HAE.
As of November 2017, the HAE therapeutics pipeline comprises of 20 drug candidates in different stages of development.
Some of the key players developing drugs for the treatment of HAE therapeutics include Shire plc, BioCryst Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc.
Scope for Customization
P&S Market Research offers customization as per specific business requirements of clients. Illustrative customization within the scope of this report includes:
Market Forecast – Market analysis and forecast for the drug candidates in the latest stage of development
Company Profiles – Wider company coverage in terms of detailed analysis or additional company profiles